Patient Selection for Long-Term Mechanical Circulatory Support: Is It Ever too Early for the NYHA Class III Patient?

Andrea M. Elliott, Brent C. Lampert

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Heart failure is a common condition with significant morbidity and mortality. Pharmacologic and device therapies have resulted in substantial improvements in heart failure outcomes. Despite optimal therapy, 10 % of patients progress to advanced HF, characterized by progressive symptoms, poor quality of life, and poor prognosis. The “gold-standard” treatment of advanced heart failure remains cardiac transplantation. However, the number of patients with advanced heart failure far exceeds available donor organs. Left ventricular assist devices (LVADs) were initially developed to bridge patients with hemodynamic collapse to transplantation. Their use resulted in marked improvements in survival and quality of life in select patients giving rise to increased and expanded overall implantation. Despite these improvements, patient selection and timing for LVAD therapy is still evolving. In this article, we will review a brief history of LVADs, examine patient selection, and explore the currently debated expansion of LVADs to “less sick” patients.

Original languageEnglish (US)
Pages (from-to)13-19
Number of pages7
JournalCurrent Heart Failure Reports
Volume13
Issue number1
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

Keywords

  • Heart failure
  • LVAD
  • Patient selection
  • Ventricular assist device

Fingerprint Dive into the research topics of 'Patient Selection for Long-Term Mechanical Circulatory Support: Is It Ever too Early for the NYHA Class III Patient?'. Together they form a unique fingerprint.

Cite this